COVID-19 Vaccination for Cancer Patients : Progress and Preliminary Recommendations
The pandemic of coronavirus disease 2019 (COVID-19) has had a serious impact on global health. COVID-19 vaccines may be one of the most effective measure to end the pandemic. High infection risk and higher serious incident and mortality rates have been shown in cancer patients with COVID-19. Therefore, cancer patients should be the priority group for COVID-19 prevention. Until now, data of COVID-19 vaccination for cancer patients is lacking. We review the interim data of safety and immune-efficacy of COVID-19 vaccination in cancer patients based on the latest studies. Due to the complicated immune systems of cancer patients caused by the malignancy and anticancer treatments, we proposed preliminary specific COVID-19 vaccination recommendations for cancer patients with different anticancer treatments and at different stages of the disease. Preventing COVID-19 with vaccinations for cancer patients is crucial, and we call for more large-scale clinical trials and real-world studies, for further COVID-19 vaccination recommendations development.
.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 24(2021), 6 vom: 20. Juni, Seite 377-383 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Wang, Luo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 12.07.2021 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3779/j.issn.1009-3419.2021.101.18 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325733805 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325733805 | ||
| 003 | DE-627 | ||
| 005 | 20231225193051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3779/j.issn.1009-3419.2021.101.18 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325733805 | ||
| 035 | |a (NLM)34024060 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Wang, Luo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Vaccination for Cancer Patients |b Progress and Preliminary Recommendations |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The pandemic of coronavirus disease 2019 (COVID-19) has had a serious impact on global health. COVID-19 vaccines may be one of the most effective measure to end the pandemic. High infection risk and higher serious incident and mortality rates have been shown in cancer patients with COVID-19. Therefore, cancer patients should be the priority group for COVID-19 prevention. Until now, data of COVID-19 vaccination for cancer patients is lacking. We review the interim data of safety and immune-efficacy of COVID-19 vaccination in cancer patients based on the latest studies. Due to the complicated immune systems of cancer patients caused by the malignancy and anticancer treatments, we proposed preliminary specific COVID-19 vaccination recommendations for cancer patients with different anticancer treatments and at different stages of the disease. Preventing COVID-19 with vaccinations for cancer patients is crucial, and we call for more large-scale clinical trials and real-world studies, for further COVID-19 vaccination recommendations development. | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer patients | |
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Vaccines | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Xu, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Junping |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Ruili |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jinglan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Mengzhao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhongguo fei ai za zhi = Chinese journal of lung cancer |d 1998 |g 24(2021), 6 vom: 20. Juni, Seite 377-383 |w (DE-627)NLM199966222 |x 1999-6187 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2021 |g number:6 |g day:20 |g month:06 |g pages:377-383 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.18 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2021 |e 6 |b 20 |c 06 |h 377-383 | ||